Debrisoquine oxidation in schizophrenic patients treated with neuroleptics.
Spina
E
E
Institute of Pharmacology, University of Messina, Italy.
Buemi
A L
AL
Caputi
A P
AP
Benitez
J
J
Cobaleda
J
J
Garcia
M A
MA
Llerena
A
A
Piña
B
B
D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002746:Chlorpromazine / Q000494:pharmacology; D003647:Debrisoquin / Q000031:analogs & derivatives / Q000097:blood / Q000378:metabolism*; D005260:Female; D006801:Humans; D006900:Hydroxylation; D007546:Isoquinolines / Q000378:metabolism*; D008297:Male; D008728:Methotrimeprazine / Q000494:pharmacology; D008875:Middle Aged; D010084:Oxidation-Reduction; D012559:Schizophrenia / Q000188:drug therapy / Q000378:metabolism*; D013881:Thioridazine / Q000494:pharmacology
D014150:Antipsychotic Agents; D007546:Isoquinolines; C012359:4-hydroxydebrisoquin; D008728:Methotrimeprazine; D013881:Thioridazine; D002746:Chlorpromazine; D003647:Debrisoquin